TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03586843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
Study: NCT03819088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Given PO
Study: NCT01533038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift System
Description: The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate
Description: Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
Study: NCT00493883

Intervention type: DEVICE
Group type: OTHER
Intervention: yttrium Y 90 microspheres (TheraSphere®)
Description: Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
Study: NCT03586843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
Study: NCT03230175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX01
Description: TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection and debridement
Description: Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics
Description: Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-loading
Description: Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
Study: NCT02409420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy informed by Acceptance and Commitment Therapy
Description: PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
Study: NCT01465191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
Study: NCT01437631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic clip application
Description: prophylactic clip application after colonoscopic polypectomy
Study: NCT03752853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based intervention for mild to moderate depression
Description: The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based intervention for mild to moderate depression
Description: The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
Study: NCT00379353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 100 mg capsules orally, once a day for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules orally, once a day for 14 days.
Study: NCT01151280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WallFlex Biliary Fully Covered Stent
Description: Investigational device evaluated for the treatment for benign biliary strictures
Study: NCT04783337

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-pQCT (high resolution computertomograph)
Description: In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
Study: NCT04338945

Intervention type: BEHAVIORAL
Intervention: COVID-surgRES questionaire
Description: The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
Study: NCT00110383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Supervised Asthma Therapy
Description: Child's inhaled steroid use supervised daily at school
Study: NCT01723501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine
Description: 0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
Study: NCT04783337

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
Study: NCT01610050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102
Study: NCT02083809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous oxytocin
Description: 30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Fluids and Electrolytes
Description: 500 ml of inert IV fluid
Study: NCT02607839

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: glucose or normal saline
Description: 20% glucose solution or normal saline, intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: glucose or normal saline
Description: 20% glucose solution or normal saline, intravenous infusion
Study: NCT00558779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OBCAB (Off Pump Coronary Artery Bypass Grafting)
Description: OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG (coronary artery bypass grafting)
Description: conventional CABG with cardiopulmonary bypass
Study: NCT03764488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MAG3-BIIB067
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MAG3-BIIB067
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MAG3-BIIB067
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MAG3-BIIB067
Description: Administered as specified in the treatment arm.
Study: NCT01171664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, one BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAHIST
Description: STAHIST in tablet form dosed one BID
Study: NCT01205178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
Study: NCT05438641

Intervention type: DRUG
Intervention: BZDP-Sparing Protocol
Description: BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.

Intervention type: DRUG
Intervention: BZDP-Based Protocol
Description: Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
Study: NCT01025765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
Study: NCT02034071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04632914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk stabilizing exercise
Description: trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac rehabilitation programe
Description: all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation programe
Description: all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
Study: NCT03128151

Intervention type: BEHAVIORAL
Intervention: Educational program for clinicians: implementation of a package of clinical prevention measures of NMB
Description: Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
Study: NCT01411072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
Study: NCT02028871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00602745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: intravenous bolus
Study: NCT01889160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4721 Solution
Description: 1-9 mg/mL liquid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4721 Solution
Description: 1-9 mg/mL liquid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4721 Placebo
Description: Liquid solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4721 Suspension
Description: 9 mg/g liquid suspension
Study: NCT00915070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BQ-123
Description: 60 mcg/min, infusion period: 60 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BQ-123
Description: 60 mcg/min, infusion period: 60 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution
Description: infusion period 60 minutes
Study: NCT01723501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: Sterile water wipes (placebo)
Study: NCT01353833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
Study: NCT00915070

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Description: infusion period 60 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
Study: NCT00996723

Intervention type: DRUG
Group type: OTHER
Intervention: vandetanib and dasatinib
Description: Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
Study: NCT03309046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REACH Individual Session
Description: Individual telephone session with parent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Webinar
Description: Videos with information on caregiving
Study: NCT02354482

Intervention type: BEHAVIORAL
Intervention: Patient Communication and Care Management
Description: Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers

Intervention type: BEHAVIORAL
Intervention: Home-Based Trust, Plain Language, and Coordination
Description: Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment

Intervention type: BEHAVIORAL
Intervention: Hospital-Based Trust, Plain Language, and Coordination
Description: Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers

Intervention type: BEHAVIORAL
Intervention: Patient/Caregiver Assessment and Provider Information Exchange
Description: Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment

Intervention type: BEHAVIORAL
Intervention: Assessment and Teach Back
Description: Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills

Intervention type: OTHER
Intervention: Standard of Care (Reference)
Description: No specific Transitional Care Strategy
Study: NCT03839927

Intervention type: OTHER
Intervention: Validity and reliability of Life-Space Assesment
Description: Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
Study: NCT01353833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aldesleukin
Description: 0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
Study: NCT00328198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study.
Study: NCT03783702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg (milligram) Oral Tablet
Description: Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyCODONE 5 Mg (milligram) Oral Tablet
Description: Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.